Business Description
Ascendis Pharma AS
NAICS : 325411
SIC : 2833
ISIN : US04351P1012
Description
Financial Strength
3/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Cash-To-Debt | 0.79 | |||||
Equity-to-Asset | -0.09 | |||||
Debt-to-Equity | -8.1 | |||||
Debt-to-EBITDA | -2.94 | |||||
Piotroski F-Score | 5/9 | |||||
Altman Z-Score | 0.03 | |||||
Beneish M-Score | -3 | |||||
WACC vs ROIC |
Growth Rank
10/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | 213.9 | |||||
3-Year EBITDA Growth Rate | 6.7 | |||||
3-Year EPS without NRI Growth Rate | -6.4 | |||||
3-Year FCF Growth Rate | -8.9 | |||||
Future 3-5Y Total Revenue Growth Rate | 54.66 |
Momentum Rank
9/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
5-Day RSI | 80.29 | |||||
9-Day RSI | 69.42 | |||||
14-Day RSI | 63.1 | |||||
6-1 Month Momentum % | 2.56 | |||||
12-1 Month Momentum % | 46.34 |
Liquidity Ratio
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Current Ratio | 1.16 | |||||
Quick Ratio | 0.84 | |||||
Cash Ratio | 0.75 | |||||
Days Inventory | 1679.76 | |||||
Days Sales Outstanding | 41.27 | |||||
Days Payable | 708.56 |
Dividend & Buy Back
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -1.7 | |||||
Shareholder Yield % | -2.12 |
Profitability Rank
3/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Gross Margin % | 84.83 | |||||
Operating Margin % | -96.31 | |||||
Net Margin % | -130.13 | |||||
FCF Margin % | -82.43 | |||||
ROA % | -49.11 | |||||
ROIC % | -50.22 | |||||
ROC (Joel Greenblatt) % | -198.86 | |||||
ROCE % | -98.76 |
GF Value Rank
2/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
PS Ratio | 21.71 | |||||
EV-to-EBIT | -305.47 | |||||
EV-to-Forward-EBIT | -13.75 | |||||
EV-to-EBITDA | -320.13 | |||||
EV-to-Forward-EBITDA | -14.48 | |||||
EV-to-Revenue | 266.87 | |||||
EV-to-Forward-Revenue | 17.09 | |||||
EV-to-FCF | -28.61 | |||||
Price-to-Median-PS-Value | 0.09 | |||||
Earnings Yield (Greenblatt) % | -0.33 | |||||
FCF Yield % | -0.24 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Annualized Return % Â
Total Annual Return % Â
Ascendis Pharma AS Executives
DetailsAnalyst Estimate
Key Statistics
Name | Value | ||
---|---|---|---|
Revenue (TTM) (Mil €) | 327.427 | ||
EPS (TTM) (€) | -7.47 | ||
Beta | 0.57 | ||
Volatility % | 38.48 | ||
14-Day RSI | 63.1 | ||
14-Day ATR (€) | 2.488172 | ||
20-Day SMA (€) | 119.55 | ||
12-1 Month Momentum % | 46.34 | ||
52-Week Range (€) | 91.5 - 147 | ||
Shares Outstanding (Mil) | 59.76 |
Piotroski F-Score Details
Component | Result | ||
---|---|---|---|
Piotroski F-Score | 5 | ||
Positive ROA | |||
Positive CFROA | |||
Higher ROA yoy | |||
CFROA > ROA | |||
Lower Leverage yoy | |||
Higher Current Ratio yoy | |||
Less Shares Outstanding yoy | |||
Higher Gross Margin yoy | |||
Higher Asset Turnover yoy |
Ascendis Pharma AS Filings
Filing Date | Document Date | Form | ||
---|---|---|---|---|
No Filing Data |
Ascendis Pharma AS Stock Events
Event | Date | Price(€) | ||
---|---|---|---|---|
No Event Data |
Ascendis Pharma AS Frequently Asked Questions
What is Ascendis Pharma AS(FRA:A71)'s stock price today?
When is next earnings date of Ascendis Pharma AS(FRA:A71)?
Does Ascendis Pharma AS(FRA:A71) pay dividends? If so, how much?
Press Release
Subject | Date | |||
---|---|---|---|---|
No Press Release |